definiens: ) and Boehringer Ingelheim RCV GmbH & Co KG ( ), an AFFILIATE ( as defined hereafter ) of BI, ente red into a previous supply agreement relating to th e commercial supply of Actimmune ® ( as described below ) dated 29 June, 2007 ( ) pursuant to the Termination Agreement dated 6 Ju ne 2007 ( ) terminating the Data Transfer, Clinical Trial an d Market Supply Agreement dated 27 January 2000, as amended ( the ) ; and Whereas, Vidara Therapeutics Research Limited ( ) ( now HORIZON, as described below ) and BI RCV entered into a consolidated suppl y agreement effective as of 31 July 2013, as amende d ( the ) ; and Whereas, the CONSOLIDATED SUPPLY AGREEMENT was assigned fro m BI RCV to its AFFILIATE BI, effective as of 1 January 2014, via a n assignment letter acknowledged by VIDARA on 13 December 2013 ; and Whereas, Vidara Therapeutics International plc, the parent company of VIDARA merged with Horizon Pharma Public Limited Company, an AFFILIATE of HORIZON, on 19 September 2014, and as of this date VIDARA was renamed and traded as HORIZON ; and Whereas, HORIZON ’s AFFILIATE Horizon Pharma Plc and BI ent ered into a technology transfer and development agreement, effective as of 9 Februa ry 2015 ( ) as [ … * * * … ] the CONSOLIDATED SUPPLY AGREEMENT ; an d Whereas, HORIZON terminated the LYOPHILISATION DEVELOPMENT AGREEMENT for convenience with termination letter of 15 September 2015 and effective as of 30 September 2016 ; and Whereas, HORIZON is expected to become the exclusive license e of and the holder of an exclusive sublicense under a license from [ … * * * … ] ; and Whereas, BII ( as defined hereafter ) had originally obtained exclusive licenses from GENENTECH to manufacture, use and sell INTERFERON GAMMA 1b in Europe and certain other territories under the tra de - mark Imukin ®, Immukin ®, Imukine ® and/or Immukine ® ( “ BI- * * * Confidential Treatment Requested Page 3 of 138 CONFIDENTIAL CorA : 151373 GENENTECH LICENSE AGREEMENTS ” ) . BII and HORIZON ’s AFFILIATE HZNP Limited entere d into an asset purchase agreement ( ), effective as of May 18, 2016, as amended, under which HORIZON acquired all rights, t itle and interest from BII to INTERFERON GAMMA 1b, including the relevant confidential information and trademarks, in the BII territory